Benefit-risk evaluation: the past, present and future

被引：26

作者：

Juhaeri, Juhaeri ^{[1
]}

机构：

[1] Sanofi, 55 Corp Dr, Bridgewater, NJ 08807 USA

来源：

THERAPEUTIC ADVANCES IN DRUG SAFETY | 2019年 / 10卷

关键词：

benefit-risk; methods; patient; preference; quantitative; structured; weight; DECISION-ANALYSIS; PATIENTS PREFERENCES; PATIENT; PHYSICIAN;

D O I：

10.1177/2042098619871180

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the last two decades there has been a shift in the approach to evaluating the benefit-risk (BR) profiles of medicinal products from an unstructured, subjective, and inconsistent, to a more structured and objective, process. This article describes that shift from a historical perspective; the past, the present, and the future, and highlights key events that played critical roles in changing the field.

引用

页数：10

共 43 条

[1] RISK AND BENEFIT EVALUATION IN DEVELOPMENT OF PHARMACEUTICAL PRODUCTS
AARON, CS
HARBACH, PR
MATTANO, SS
MAYO, JK
WANG, Y
YU, RL
ZIMMER, DM
[J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 1993, 101 : 291 - 295
[2] [Anonymous], 2018, Benefit-risk assessment in drug regulatory decision-making: draft PDUFA VI implementation plan (FY 2018-2022)
[3] [Anonymous], STRUCT APPR BEN RISK
[4] MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING
Banos Roldan, Ursula
Badia, Xavier
Antonio Marcos-Rodriguez, Jose
de la Cruz-Merino, Luis
Gomez-Gonzalez, Jaime
Melcon-de Dios, Ana
Caraballo-Camacho, Maria de la O.
Cordero-Ramos, Jaime
Dolores Alvarado-Fernandez, Maria
Manuel Galiana-Auchel, Jose
Angel Calleja-Hernandez, Miguel
[J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (05) : 519 - 526
[5] COCCHETTO DM, 1986, PHARMACOTHERAPY, V6, P286
[6] THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT
COOK, RJ
SACKETT, DL
[J]. BRITISH MEDICAL JOURNAL, 1995, 310 (6977) : 452 - 454
[7] Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit-Risk Balance of Medicines
Coplan, P. M.
Noel, R. A.
Levitan, B. S.
Ferguson, J.
Mussen, F.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 312 - 315
[8] Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project
de Bekker-Grob, Esther W.
Berlin, Conny
Levitan, Bennett
Raza, Karim
Christoforidi, Kalliopi
Cleemput, Irina
Pelouchova, Jana
Enzmann, Harald
Cook, Nigel
Hansson, Mats G.
[J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2017, 10 (03) : 263 - 266
[9] Concepts in risk-benefit assessment - A simple merit analysis of a medicine?
Edwards, IR
Wiholm, BE
Martinez, C
[J]. DRUG SAFETY, 1996, 15 (01) : 1 - 7
[10] European Medicines Agency, 2018, Committee for Medicinal Products for Human Use (CHMP) Assessment report Yescarta, axicabtagene ciloleucel

← 1 2 3 4 5 →